Single Point Partners LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 12,995 shares of the biopharmaceutical company’s stock after selling 443 shares during the quarter. Single Point Partners LLC’s holdings in Pfizer were worth $666,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the company. Worth Asset Management LLC bought a new stake in Pfizer during the first quarter valued at about $29,000. Karp Capital Management Corp bought a new stake in shares of Pfizer during the third quarter valued at approximately $27,000. Delos Wealth Advisors LLC raised its position in shares of Pfizer by 100.0% during the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 400 shares during the last quarter. Legend Financial Advisors Inc. bought a new stake in shares of Pfizer during the third quarter valued at approximately $42,000. Finally, New Millennium Group LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $53,000. Hedge funds and other institutional investors own 67.62% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the stock. BMO Capital Markets reduced their price objective on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 1st. UBS Group set a $45.00 price target on shares of Pfizer in a research report on Tuesday. Wells Fargo & Company reduced their price target on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Friday. StockNews.com assumed coverage on shares of Pfizer in a research report on Thursday. They issued a “buy” rating on the stock. Finally, Credit Suisse Group reduced their price target on shares of Pfizer from $54.00 to $50.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 1st. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $50.38.
Pfizer Stock Down 0.7 %
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The company had revenue of $24.30 billion during the quarter, compared to analyst estimates of $24.40 billion. During the same period in the prior year, the firm earned $1.08 earnings per share. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 3.33 EPS for the current fiscal year.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.